Clinical Trials Arena on MSN
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.
Tezepelumab reduced exacerbations across all seasons in severe uncontrolled asthma, even among patients with perennial and seasonal allergies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback